The REstart or STop Antithrombotics Randomised Trial (RESTART) after stroke due to intracerebral haemorrhage: statistical analysis plan for a randomised controlled trial

Rustam Al-Shahi Salman, Gordon D Murray, Martin S Dennis, David E Newby, Peter A G Sandercock, Nikola Sprigg, Cathie L M Sudlow, David J Werring, Philip M White, William N Whiteley

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: For adults surviving stroke due to spontaneous (non-traumatic) intracerebral haemorrhage (ICH) who had taken an antithrombotic (i.e. anticoagulant or antiplatelet) drug for the prevention of vaso-occlusive disease before the ICH, it is unclear whether starting antiplatelet therapy modifies the risks of recurrent ICH, major haemorrhagic events, major occlusive vascular events, or a composite of all major vascular events compared to avoiding antiplatelet therapy.

METHODS/DESIGN: The REstart or STop Antithrombotics Randomised Trial (RESTART) is an investigator-led, parallel group, open, assessor-blind, randomised trial comparing starting versus avoiding antiplatelet therapy for adults surviving antithrombotic-associated ICH. Recruitment began on 22 May 2013 and ended on 31 May 2018. Follow-up ended on 30 November 2018. This update to the protocol describes the statistical analysis plan (version 1.7, finalised on 25 January 2019). Database lock and un-blinding occurred on 29 January 2019, after which the un-masked trial statistician conducted the final analyses according to this statistical analysis plan.

DISCUSSION: Final results of RESTART will be analysed and disseminated in May 2019.

TRIAL REGISTRATION: ISRCTN registry 71907627 . Prospectively registered on 25 April 2013.

Original languageEnglish
Pages (from-to)183
JournalTrials
Volume20
Issue number1
DOIs
Publication statusPublished - 25 Mar 2019

Fingerprint Dive into the research topics of 'The REstart or STop Antithrombotics Randomised Trial (RESTART) after stroke due to intracerebral haemorrhage: statistical analysis plan for a randomised controlled trial'. Together they form a unique fingerprint.

Cite this